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Quantitative Proteomic Analysis of
Burkholderia pseudomallei Bsa Type III
Secretion System Effectors Using
Hypersecreting Mutants□S
Charles W. Vander Broek‡, Kevin J. Chalmers§, Mark P. Stevens‡,
and Joanne M. Stevens‡¶
Burkholderia pseudomallei is an intracellular pathogen and
the causative agent of melioidosis, a severe disease of
humans and animals. One of the virulence factors critical
for early stages of infection is the Burkholderia secretion
apparatus (Bsa) Type 3 Secretion System (T3SS), a molec-
ular syringe that injects bacterial proteins, called effectors,
into eukaryotic cells where they subvert cellular functions
to the benefit of the bacteria. Although the Bsa T3SS itself is
known to be important for invasion, intracellular replication,
and virulence, only a few genuine effector proteins have been
identified and the complete repertoire of proteins secreted by
the system has not yet been fully characterized. We con-
structed amutant lackingbsaP, a homolog of the T3SS “gate-
keeper” family of proteins that exert control over the timing
and magnitude of effector protein secretion. Mutants lacking
BsaP, or the T3SS translocon protein BipD, were observed to
hypersecrete the known Bsa effector protein BopE, providing
evidence of their role in post-translational control of the Bsa
T3SS and representing key reagents for the identification of
its secreted substrates. Isobaric Tags for Relative and Abso-
luteQuantification (iTRAQ), a gel-free quantitative proteomics
technique, was used to compare the secreted protein profiles
of the Bsa T3SS hypersecreting mutants of B. pseudomallei
with the isogenic parent strain and a bsaZmutant incapable
of effector protein secretion. Our study provides one of the
most comprehensive core secretomes of B. pseudomallei
described to date and identified 26 putative Bsa-dependent
secreted proteins that may be considered candidate effec-
tors. Two of these proteins, BprD and BapA, were validated
as novel effector proteins secreted by the Bsa T3SS of
B. pseudomallei. Molecular & Cellular Proteomics 14:
10.1074/mcp.M114.044875, 905–916, 2015.
Burkholderia pseudomallei is a Gram-negative environmental
saprophyte found in free-standing water and soil (1). The causa-
tive agent of melioidosis, B. pseudomallei causes severe disease
in humans and animals with a range of clinical manifestations
including severe pneumonia and septic shock, acute or chronic
suppurative infections, genitourinary disease, and asymptomatic
carriage (2). An emerging infectious disease, melioidosis is found
primarily in South East Asia and Northern Australia, yet there is a
growing body of evidence of a more widespread distribution in
subtropical regions of Asia, the Americas, and Africa (3). Melioid-
osis is an important cause of community-acquired septicaemia in
North-East Thailand, where it can cause mortality rates of up to
40% (4). Because of the lack of an effective vaccine, intrinsic
antibiotic resistance, and the high mortality rates, there is a need
to better understand the molecular mechanisms of pathogenesis
to inform the design of treatments and vaccines (5).
B. pseudomallei is a facultative intracellular pathogen ca-
pable of invading both phagocytic and nonphagocytic cells
(6). Once inside the cell, the bacteria can rapidly escape the
endosome and polymerize host cell actin at one pole causing
actin-based motility, a process dependent on the bacterial
BimA protein (7). B. pseudomallei also causes host cell fusion
creating multinucleated giant cells (MNGCs) that facilitates
cell to cell spread while evading immune detection (8). The
formation of MNGCs by B. pseudomallei is dependent on
secretion of the protein VgrG5 by the virulence-associated
type VI secretion system-5 (9–12).
One important virulence factor of B. pseudomallei that has
also been shown to be important for infection in many other
Gram-negative bacteria including pathogenic Escherichia coli,
Salmonella, Shigella, and Yersinia, is the Type III Secretion
System (T3SS)1 (13–16). T3SSs act as a molecular syringe
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projecting outwards from the surface of the bacteria allowing
for the transport of bacterial proteins into target eukaryotic
cells (17). These bacterial proteins, termed effectors, subvert
host cell processes to the advantage of the bacteria and rely
on a second class of T3SS-secreted proteins (translocators)
for delivery (18). B. pseudomallei contains three T3SSs, of
which T3SS-1 and T3SS-2 share homology with T3SSs found
in plant pathogens (19, 20). T3SS-3, also known as the Burk-
holderia Secretion Apparatus (Bsa) T3SS, is similar to the
Inv-Spa (Salmonella pathogenicity island (SPI)-1) and Mxi-Spa
T3SSs of the animal pathogens Salmonella spp. and Shigella
flexneri respectively (21). The Bsa T3SS has been shown to be
important in invasion, endosome escape and net intracellular
replication in cultured cells and in virulence in murine and
Syrian hamster models of melioidosis (21–24).
As the Bsa system influences pathogenesis, one may infer
that its effectors also influence the outcome of infection.
However, only three effectors, BopE, BopC, and CHBP, have
so far been proven to be secreted by B. pseudomallei in a Bsa
T3SS-dependent manner (25–27). BopE is a guanine nucleo-
tide exchange factor that is involved in invasion of nonphago-
cytic cells (26). BopC has been shown to be important for
invasion of A549 epithelial cells and endosome escape, and
intracellular survival in J774A.1 macrophage-like cells (25, 28).
CHBP is a homolog of E. coli Cif, a cyclomodulin that disrupts
the eukaryotic cell cycle (29), for which evidence of Bsa-de-
pendent translocation into host cells was recently presented
(27). A fourth candidate effector, BopA, prevents LC3-asso-
ciated host autophagy of intracellular bacteria and has been
shown to be secreted in a T3SS-dependent manner in a
surrogate enteropathogenic E. coli (EPEC) host (30, 31). Com-
pared with the large number of effectors secreted by T3SSs in
other Gram-negative pathogens, it is likely that there are other
effectors of the Bsa T3SS yet to be characterized (32). Bsa-
secreted proteins are known to be potent B- and T-cell anti-
gens in humans (33–36) and subunit vaccines based on nee-
dle components or effectors are protective against other
pathogens that deploy T3SSs (e.g. Shigella IpaB and IpaD,
Yersinia V antigen, Salmonella SseI) (37–41).
One of the problems facing T3SS effector protein discovery
is the tight regulation of the T3SS under laboratory conditions
with different T3SSs responding to very different environmen-
tal cues (42–47). Although some genes involved in transcrip-
tional control of the Bsa T3SS were recently identified (48),
little is known about the post-translational regulation of the
system and what environmental signals may activate it. In-
deed, a recent proteomics study of B. pseudomallei failed to
identify any of the known Bsa T3SS effectors in bacterial
culture supernatants (49). To override the tight control of the
T3SS, one solution employed in the study of other Gram-
negative bacteria (for example EPEC and Citrobacter roden-
tium) was to generate mutations of T3SS components that
dysregulate the system, thereby creating a hypersecretion
phenotype. The bacterial supernatants were then analyzed
using gel-free quantitative proteomics techniques to identify a
range of novel effector proteins (50, 51).
In Shigella, deletion of IpaD, the needle tip protein, creates
a “leaky” phenotype, in which higher levels of both transloca-
tors and effectors are seen in the supernatant (46, 52). The
homolog of IpaD in B. pseudomallei is BipD (53) (supplemen-
tal Fig. S1). In a previous study, we have shown a 10276
bipD::pDM4 mutant secreted higher levels of the effector
protein BopE into the bacterial culture supernatant by West-
ern blot analysis, but it is unknown what effect bipD disruption
may have on the secretion of other effectors and translocators
(26).
Another group of T3SS proteins that have been shown in
many systems to be involved in the control of effector and
translocator secretion are the so called “gatekeeper” family of
proteins, InvE/MxiC/SepL/YopN-TyeA of Salmonella/Shigella/
E. coli/Yersinia, respectively (17). Investigation of these pro-
teins has given insight into the temporal regulation of their
respective T3SSs. Although deletion of all of these proteins
causes an increase in levels of secreted effectors there are
also differences between them. Deletion of InvE and SepL
cause a reduction in secreted levels of translocators, deletion
of MxiC has no effect on their levels, and deletion of YopN
increases levels of secreted translocators (54–60). The clos-
est homolog to this family of proteins in B. pseudomallei is the
uncharacterized protein BsaP (BPSS1544) (supplemental
Fig. S1).
Here, a 10276 bsaP deletion mutant was generated and its
effect on secreted levels of the known effector BopE was
assessed. To define the total and Bsa-dependent repertoire of
secreted proteins, Isobaric Tags for Relative and Absolute
Quantification (iTRAQ), a gel-free quantitative proteomics
technique, was used to quantify protein levels in the bacterial
culture supernatants of B. pseudomallei mutant strains 10276
bipD::pDM4 and 10276 bsaP. In order to identify candidate
Bsa effector proteins, the secreted protein profiles from these
hypersecreting mutants were then compared with the iso-
genic parent strain (10276 WT) and a T3SS structural-null
mutant (10276 bsaZ::pDM4), which has been shown to be
unable to secrete BipD and BopE (21). BsaZ is a homolog of
YscU in Yersinia, which forms a key component of the inner
membrane ring and is required for a functional T3SS (61)
(supplemental Fig. S1). From this analysis we provide the first
evidence of the involvement of both BipD and BsaP in control
of known effector/translocator secretion in the Bsa T3SS. We
also present a comprehensive general secretome for B. pseu-
domallei. Furthermore, we have identified 26 candidate effec-
tor proteins, including all known Bsa-secreted effectors, of
which we show two proteins are novel substrates for secre-
tion by the Bsa T3SS.
EXPERIMENTAL PROCEDURES
Strains, Media, Plasmids, and Oligonucleotides—Bacterial strains
and plasmids are listed in supplemental Table S1. The insertion
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mutants 10276 bipD::pDM4 and 10276 bsaZ::pDM4 were produced
by integration of the pDM4 suicide vector into the coding sequence of
the target gene (21). Primers, purchased from Sigma Aldrich (Gilling-
ham, UK), are listed in supplemental Table S2. Bacteria were routinely
cultured at 37 °C on LB agar (Miller) or LB broth (Lennox). Antibiotic
selection was performed at the following concentrations unless oth-
erwise stated: ampicillin (Amp) 100 g/ml, kanamycin (Kan) 50 g/ml,
chloramphenicol (Cm) 34 g/ml, and tetracycline (Tet) 15 g/ml. IPTG
was used at a final concentration of 0.5 mM where appropriate. Unless
otherwise stated all chemicals were purchased from Sigma Aldrich
(Gillingham, UK).
B. pseudomallei Mutagenesis—The 10276 bsaP in-frame deletion
mutant was made using allelic exchange and the sacB containing
positive-selection suicide vector pDM4 essentially as previously de-
scribed (62). DNA fragments upstream and downstream of bsaP
(BPSS1544) were amplified by PCR from B. pseudomallei 10276
genomic DNA using primer pair’s bsaP-del-1/bsaP-del-2 and bsaP-
del-3/bsaP-del-4. The resulting DNA fragments were combined using
PCR-ligation-PCR (63). A-tailing was performed to add an adenosine
to the blunt-ended PCR product, which was then ligated into pGEM-T
resulting in the plasmid pGEM-T-bsaP. The insert was sequenced
and a SpeI and BglII fragment containing the 10276 bsaP fragment
ligated into similarly digested pDM4 resulting in pDM4-bsaP. To
propagate pDM4-bsaP, the plasmid was transformed into TOP 10
PIR1 cells (Life Technologies, Paisley, UK) before transfer into E. coli
S17–1 pir conjugal donor with selection for Cm resistance.
pDM4-bsaP was introduced into B. pseudomallei strain 10276 by
conjugation with E. coli S1–17 pir and plated onto LA plates con-
taining Cm (50 g/ml) and Kan (50 g/ml) to select for B. pseudomal-
leiwith pDM4-bsaP integrated into the chromosome by homologous
recombination (21). Colonies were patched onto LA plates containing
Cm (50 g/ml) and Kan (50 g/ml) to confirm resistance. Overnight
cultures of the Cmr colonies were cultured without selection to allow
for a second round of homologous recombination to take place either
restoring the full length bsaP gene or resulting in bsaP deletion. To
select for double recombinants lacking pDM4-bsaP the overnight
cultures were plated onto 15% sucrose plates lacking NaCl and
cultured at 30 °C for 3 days. Chromosomal deletion of bsaP was
confirmed in sucrose resistant/Cms colonies by colony PCR and the
resulting strain designated 10276 bsaP, where the bsaP gene has
been replaced by an in-frame start-stop (atg-taa) cassette.
Complementation of the bsaP Mutant—For complementation of
the bsaP mutant the 10276 bsaP sequence was amplified by PCR
using the forward primer bsaP-exp-F containing a ClaI restriction site
and a ribosome-binding site and the reverse primer bsaP-exp-R
containing a HindIII restriction site. The PCR fragment was cloned into
pBHR1 (MoBiTec, 2B Scientific Ltd., Oxford, UK) to create pBHR1-
bsaP. The plasmid was purified and transformed into B. pseudomallei
10276 bsaP using the fast sucrose method of electroporation (64),
creating strain 10276 bsaP-pbsaP.
Cloning of Candidate Effectors to Express c-Myc Epitope-Tagged
Fusion Proteins—The coding region for candidate effectors based on
the B. pseudomallei K96243 genome sequence were amplified from
B. pseudomallei 10276 genomic DNA by PCR with a 5 forward primer
containing a ribosome-binding site and a 3 reverse primer encoding
an in-frame c-Myc tag followed by a stop codon. Each primer also
contained a restriction site suitable for directional insertion into the
vector pME6032. Plasmids were transformed into E. coli and the
inserts sequenced. Purified plasmids were then transformed into B.
pseudomallei 10276 (WT), 10276 bsaZ::pDM4, 10276 bipD::pDM4,
and 10276 bsaP.
Preparation of Bacterial Culture Supernatants—Preparation of B.
pseudomallei supernatants was performed by first centrifuging over-
night cultures at 3220 RCF for 10 min at 4 °C followed by disposal of
the supernatant and resuspension of the bacteria in fresh LB to an
OD600 of 1.0. Of the bacterial suspension, 1 ml was then added to 10
ml of LB containing the appropriate antibiotics and IPTG if needed.
The culture was incubated for 6 h shaking at 200 RPM at 37 °C. To
determine the initial and final bacterial counts, a sample was removed
from the culture before and after the 6 h incubation for serial dilution
and plating on LA plates. After 6 h, the sample was centrifuged at
3220 RCF for 10 min at 4 °C. The culture supernatant was collected
and centrifuged a second time to ensure no intact bacteria remained.
The supernatant was then passed through a 0.2 m low protein
binding cellulose acetate membrane filter (Millipore, Watford, UK) and
sterility tested.
Protein Precipitation—Proteins were precipitated using a Pyrogallol
red-molybdate methanol (PRMM) solution (0.5 mM pyrogallol red (Alfa
Aesar, Heysham, UK), 0.16 mM sodium molybdate, 1.0 mM sodium
oxalate, 50 mM succinic acid, 20% MeOH, pH 2.0) as previously
described (65). In brief, equal volumes of bacterial culture supernatant
and PRMM solution were thoroughly mixed and the pH was adjusted
to 2.8  0.1 with HCl. The samples were then precipitated overnight
at 4 °C. The resulting precipitate was centrifuged at 3220 RCF, 4 °C
for 1 h and the supernatant was discarded. The pellet was washed
twice with ice-cold acetone and then allowed to air dry. The protein
pellet was then solubilized in 50 mM ammonium bicarbonate and
quantified using a Direct Detect Infrared Spectrometer (Millipore,
Watford, UK).
SDS-PAGE and Immunoblotting—Proteins were separated using
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Equal volumes of protein samples and Laemmli buffer were
mixed and heated to 90 °C for 5 min. Samples were separated on Any
kDa™ Mini-PROTEAN® TGX gels (Bio-Rad, Hemel Hempstead, UK)
at 150V for 45 min in Tris-Glycine running buffer. Proteins were
visualized by Coomassie staining. Western blots were used to identify
particular proteins of interest. Proteins were transferred onto a nitro-
cellulose membrane using the Trans-Blot Turbo system (Bio-Rad,
Hemel Hempstead, UK) at 2.5 A for 3 min. -BopE (26), -BipD (22),
or -cMyc (Insight Biotechnology, Wembley, UK) rabbit polyclonal
antibodies were used at 1 g/ml. For detection by infrared fluores-
cence, goat-  -rabbit IgG (HL) (DyLight™ 800 Conjugate) was used
at a 1:10,000 dilution (Cell Signaling Technology, Hitchin, UK). Blots
were visualized using an Odyssey Infrared Imaging System (LI-COR
Biosciences, Cambridge, UK) according to the manufacturer’s in-
structions. Images were captured and analyzed using Image Studio
Lite (LI-COR Biosciences, Cambridge, UK).
iTRAQ Experimental Design—Bacterial culture supernatants of B.
pseudomallei 10276 WT, 10276 bsaZ::pDM4, 10276 bipD::pDM4, and
10276 bsaP were generated in three independent experiments.
Equal amounts of protein from each replicate were combined creating
a single pooled sample for each strain. These samples were enzy-
matically digested, peptides were labeled using iTRAQ reagents, and
then pooled and submitted to LC MS/MS in three technical replicates
as follows:
(1) Protein Digestion and Peptide Fractionation—Protein samples
were prepared for MS analysis using a protocol adapted from (66).
Following protein quantification, samples were reduced in 10 mM DTT
and alkylated in 50 mM Iodoacetamide prior to heating in Laemmli
buffer, and then separated by one-dimensional SDS-PAGE (4–12%
Bis-Tris Novex mini-gel, Life Technologies, Paisley, UK) and visual-
ized by colloidal Coomassie staining (Life Technologies). The entire
protein gel lanes were excised and cut into 10 slices each. Every gel
slice was subjected to in-gel digestion with trypsin overnight at 37 °C.
The resulting tryptic peptides were extracted by formic acid (1%) and
acetonitrile, lyophilized in a speedvac, and resuspended in 1% formic
acid.
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(2) Peptide Concentration—To determine the concentration of the
peptides, the dried samples were resuspended in 100 mM TEAB 1 M
ACN. To determine the volume of sample needed for an even protein
load across all samples, 1 l was injected onto an LTQ Velos Mass
Spectrometer (Thermo Fisher Scientific, MA) and the TIC trace was
used.
(3) iTRAQ Labeling—Samples were labeled according to the man-
ufacturer’s instructions using an iTRAQ Reagents Multiplex kit – four-
plex (AB Sciex UK Ltd., Warrington, UK). To each vial of labeling
reagent (labels- 114, 115, 116, and 117), 70 l ethanol was added,
after which they were vortexed and centrifuged. A single vial of label
was added to a single vial of sample and mixed. The samples used
with each label were: 10276 bsaZ::pDM4–114, 10276 WT-115, 10276
bipD::pDM4–116, and 10276 bsaP-117. Samples were incubated
with shaking at room temperature for 1 h, after which 100 l of water
was added and incubated for a further hour. The four vials of labels/
samples were pooled into one vial and then dried under vacuum.
Samples were desalted using a standard method.
(4) SCX Fractionation – Salt Cuts—To a Millipore (Watford, UK) C18
ziptip, 10 l Poros HS resin (Life Technologies, Paisley, UK) was
added and washed with 3  25 l Buffer A (35% acetonitrile (ACN),
0.1% formic acid (FA)). Samples were resuspended in Buffer A and
loaded onto the resin, washed with 3 25 l Buffer A, and eluted with
2  25 l of each of 11 salt cuts ranging from 5 mM to 800 mM NaCl.
A final elution was performed using 2 25 l 50% isopropanol, 0.4%
ammonium hydroxide. Samples were centrifuged and speed vacu-
umed until dry. Samples were resuspended in 1% FA and pooled as
six samples containing the salt cuts as follows: JS-1 (5 mM, 10 mM, 20
mM), JS-2 (50 mM), JS-3 (100 mM), JS-4 (150 mM), JS-5 (200 mM), and
JS-6 (250 mM, 300 mM, 400 mM, 800 mM).
Mass Spectrometry—Peptides were separated using an Ultimate
3000 RSLC nanoflow LC system (Thermo Fisher Scientific, MA). With
a constant flow of 5 l/min, 15 l of sample was loaded onto an
Acclaim PepMap100 nanoViper C18 trap column (100 m inner-
diameter, 2 cm) (Thermo Fisher Scientific, MA). After trap enrichment,
peptides were eluted onto an Acclaim PepMap RSLC nanoViper, C18
column (75 m, 15 cm) (Thermo Fisher Scientific, MA) with a linear
gradient of 2–45% solvent B (80% ACN with 0.08% FA) over 125 min
with a constant flow of 300 nl/min. The HPLC system was coupled to
a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap
Velos) (Thermo Fisher Scientific, MA) via a nanoelectrospray ion
source (Thermo Fisher Scientific, MA). The spray voltage was set to
1.2kV and the temperature of the heated capillary was set to 250 °C.
Full-scan MS survey spectra (m/z 335–1800) in profile mode were
acquired in the Orbitrap with a resolution of 60,000 after accumulation
of 1,000,000 ions. The ten most intense peptide ions from the preview
scan in the Orbitrap were fragmented sequentially by higher-energy
collisional dissociation (HCD) (two-step (6%) normalized collision en-
ergy (NCE), 40%; and activation time, 0.1 ms) prior to analysis in the
Orbitrap after accumulation of 50,000 ions. Maximal filling times were
500 ms for the full scans and 200 ms for the MS/MS scans. Precursor
ion charge state screening was enabled, and all unassigned charge
states as well as singly charged species were rejected. The lock
mass option was enabled for survey scans to improve mass accu-
racy (67). Data were acquired using Xcalibur software (Thermo
Fisher Scientific, MA).
Quantification and Bioinformatic Analysis—The raw mass spectro-
metric data files obtained for each experiment were collated into a
single data set using Proteome Discoverer version 2.0 (Thermo Fisher
Scientific, MA) and the Mascot search engine version 2.4 (www.
matrixscience.com) using a translated B. pseudomallei K96243 ge-
nome as a reference for protein identification. Enzyme specificity was
set to that of trypsin, allowing for cleavage N-terminal to proline
residues and between aspartic acid and proline residues. Other pa-
rameters used were: 1) variable modifications, methionine oxidation,
protein N-acetylation, gln3 pyro-glu; 2) fixed modifications, cysteine
carbamidomethylation; 3) database: B. pseudomallei K96243_
20120601 (compiled 01/06/2012, containing 5728 proteins); 4) iTRAQ
labels: standard iTRAQ 4-plex quant method with labels 114–117; 5)
MS/MS tolerance: FTMS- 10ppm, FTMS/MS- 0.06Da; 6) minimum
peptide length, 6; 7) maximum missed cleavages, 2; and 8) false
discovery rate, 1%. Peptide ratios were calculated for samples using
the 10276 bsaZ::pDM4–114 label as the denominator. Data are avail-
able via ProteomeXchange with identifier PXD001656.
Protein ratios were normalized using the overall median ratio for all
quantified proteins in each sample based on the assumption that the
abundance of the majority of secreted proteins was identical in each
condition. Proteins were selected as potential T3SS effector protein
candidates if they had at least two unique peptides used in quantifi-
cation with a MASCOT peptide score 21 (which corresponds to the
threshold value for a 95% confidence level, a 1 in 20 chance that the
match is random), and a “high” iTRAQ ratio in at least one strain,
which we defined as a value greater than 1.5 IQR. IQR is defined as
Q3  3n 14 
th
term  Q1  n 14 
th
term; where n complete
set of ratios over 10276 bsaZ::pDM4 for all quantified proteins in a
given sample.
RESULTS
Construction and Characterization of Hypersecreting bsa
Mutants—We hypothesized that BsaP may control the timing
and magnitude of effector secretion based on homology to
“gatekeeper” proteins from the T3SSs of other Gram-negative
bacterial pathogens. BLAST analysis of available genomes
indicated that BsaP shares 33% identity over 92% coverage
(E-value 1e-41) with the Shigella MxiC “gatekeeper” protein
and 34% identity over 88% coverage (E-value 4e-32) with the
Salmonella InvE “gatekeeper” protein (supplemental Fig. S2).
A nonpolar bsaP deletion mutant was therefore constructed in
B. pseudomallei strain 10276 by double homologous recom-
bination using a positive-selection suicide vector containing
short regions of DNA flanking the bpss1544 gene (62). The
chromosomal deletion was confirmed by sequencing across
the bsaP adjoining regions (data not shown). Because bsaP is
predicted to reside in the middle of an operon, with seven
genes upstream and two downstream, the deletion of bsaP
was complemented using a constitutive expression vector
encoding bsaP to confirm any phenotypes were not caused
by polar effects. Alongside the bsaP mutant we also analyzed
10276 bipD::pDM4 lacking the BipD needle tip protein that
has been previously reported to secrete elevated levels of the
effector protein BopE (26).
Bacteria-free culture supernatants were collected from
B. pseudomallei 10276 WT, 10276 bsaZ::pDM4, 10276
bipD::pDM4, 10276 bsaP, and 10276 bsaP (pbsaP) and
analyzed by SDS-PAGE followed by Coomassie staining. The
secreted protein profile of B. pseudomallei LB-culture super-
natant is highly complex with few obvious differences be-
tween the strains (supplemental Fig. S3). The bacterial super-
natants and whole cell lysates were also analyzed by Western
blot using antibodies to detect the BopE effector protein and
the BipD translocon protein (Fig. 1). The absence of both
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BopE and BipD in the supernatants of the 10276 bsaZ::pDM4
insertion mutant indicates that there was no detectable cell
lysis at the time when the secretome was sampled. When
compared with the 10276 WT strain, both 10276 bipD::pDM4
and 10276 bsaP strains demonstrated increased secretion
of BopE. Interestingly, the levels of BipD secreted into the
supernatant was reduced in 10276 bsaP compared with
10276 WT. This pattern of increased levels of the effector
BopE and reduced secretion of the translocator BipD pro-
vides the first evidence of a role for BsaP as a “gatekeeper”
protein, controlling a switch between the secretion of trans-
locators and effectors. In the case of both BopE and BipD, the
phenotype of 10276 bsaP was partially restored by plasmid-
mediated complementation, indicating the effects are unlikely
to be caused by polar or secondary defects. Differences in the
levels of BopE and BipD across the different strains sampled
are not caused by differences in the number of bacteria at six
hours subculture, because the growth rates of all strains were
shown to be identical by viable count assessment (data not
shown).
Characterization of the total B. pseudomallei Secretome
under Standard Laboratory Conditions—Having identified two
bsa mutant strains with dysregulated BopE secretion profiles
in bacterial culture supernatants, we then sought to identify
the total secreted protein profile from these two strains in
comparison to the isogenic parent strain (10276) and a bsa-
null mutant strain. In three independent experiments, culture
supernatants were prepared from the four test strains at 6 h
post subculture. The strains used were B. pseudomallei
10276 WT, 10276 bsaZ::pDM4, 10276 bipD::pDM4, and
10276 bsaP (supplemental Fig. S1). The samples were all
assessed for a lack of cell lysis by immunoblotting for BopE.
All 10276 bsaZ::pDM4 samples lacked BopE, indicating the
samples were suitable for analysis (supplemental Fig. S4).
After mixing equimolar amounts of each of the three biological
replicates, the samples were subjected to iTRAQ labeling and
MS/MS analysis as described under “Experimental Proce-
dures.” iTRAQ allowed the simultaneous identification and
relative quantification of peptide fragments in all four separate
samples, resulting in the positive identification of a total of 475
proteins in all samples (listed in supplemental Table S3). The
data was expressed as ratios of relative protein abundance
either in the 10276 WT, 10276 bipD::pDM4, or 10276 bsaP
samples over the 10276 bsaZ::pDM4 sample as a denomina-
tor (i.e. 10276 WT/10276 bsaZ::pDM4, 10276 bipD::pDM4/
10276 bsaZ::pDM4, and 10276 bsaP/10276 bsaZ::pDM4).
The ratios were normalized to the median for each strain and
a density plot showed that the majority of protein ratios clus-
ter around the median of one, indicating that the mutations
made did not radically change the secretion profile of the bulk
of proteins (supplemental Fig. S5). From this analysis we
identified a core set of 426 proteins, out of the predicted total
proteome of B. pseudomallei K96243 of 	5900 proteins (68),
that were present in all samples. These are listed in supple-
mental Table S4. Strikingly, the majority of these proteins
(	80%) are encoded by Chromosome 1.
Of the proteins identified in the core secretome, 54 are
annotated with reference to the K92643 genome as hypothet-
ical (uncharacterized) proteins, several more are annotated
with metabolic functions (supplemental Table S4). The core
secretome also consisted of several elongation factors (Ts, G,
P, Tu) and heat shock/chaperone proteins (GroES, GroEL),
many of which have previously been reported to be present
on the surface of B. pseudomallei or part of the outer mem-
brane proteome and recognized by the sera of recovering
melioidosis patients (35, 69–71). In addition to the presence of
a collagenase, chitobiase, bacterioferritin, and Sec secretory
pathway constituents, the secretome also harbored several
proteases and lipoproteins. Several phage components, Type
I fimbriae, and flagellar subunits were also present, although
there was a notable lack of any of the predicted T6SS struc-
tural or effector proteins, Type V family of autotransporters or
the Type IV pilus protein PilA.
Prediction of the Bsa Effector Repertoire—Putative T3SS
effector proteins were identified in the data sets primarily on
the calculated iTRAQ protein abundance ratios. The protein
abundances obtained in each of the WT or mutant strain
samples were each expressed as a ratio of the 10276
bsaZ::pDM4 sample and proteins with an iTRAQ ratio higher
than the 1.5  interquartile range (IQR), together with at least
two unique peptides with a MASCOT peptide score 21,
were taken to be T3SS effector protein candidates. The 1.5 
IQR values were calculated and the cut-offs set at 1.56 for the
10276 WT/10276 bsaZ::pDM4 data set, 1.79 for the 10276
bipD::pDM4/10276 bsaZ::pDM4 data set, and 1.46 for the
10276 bsaP/10276 bsaZ::pDM4 data set, based on the cal-
culation described under “Experimental Procedures.” When
FIG. 1.Western blot analysis of the expression and secretion of
BopE and BipD proteins by wild-type and mutant B. pseudomallei
strains. 10276 WT, 10276 bsaZ::pDM4, 10276 bipD::pDM4, 10276
bsaP, and 10276 bsaP pbsaP were cultured for 6 h at 37 °C. Equal
quantities of protein from the whole cell lysates or cell-free superna-
tants were separated by denaturing SDS-PAGE and proteins trans-
ferred to a nitrocellulose membrane for protein detection using poly-
clonal rabbit -BopE or -BipD (26) essentially as described under
“Experimental Procedures.”
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the data was plotted as a boxplot, the data showed a trend
toward more proteins with larger ratios in the 10276
bipD::pDM4/10276 bsaZ::pDM4 and 10276 bsaP/10276
bsaZ::pDM4 data sets when compared with the 10276 WT/
10276 bsaZ::pDM4 data set (Fig. 2A). A total of 26 proteins
met the selection criteria and can be considered putative
effectors (Table I). Of the 26 proteins there were strain-spe-
cific subsets, with eight proteins with high ratios in two of the
data sets and three proteins with high ratios in all three (Fig.
2B). The three proteins that displayed high ratios in all three
data sets, BopC, BopA, and BopE, are all known B. pseu-
domallei Type III secreted (T3S) effector proteins or predicted
to be T3S proteins based on their T3SS-dependent secretion
in a surrogate host system (25, 26, 31) (Fig. 2B). Of the 26
proteins, 20 were only found in the hypersecreting mutant
strain samples and would not have been identified had our
study focused solely on the study of the secreted proteins of
the 10276 WT strain (Fig. 2B). Plotting the iTRAQ ratios of the
26 putative effector proteins against their B. pseudomallei
K96243 genetic locus number, it is clear that there is a con-
centration of eight proteins with especially high ratios en-
coded within the annotated bsa T3SS locus on Chromosome
2 compared with that of the rest of the genome (Table I,
Fig. 2C).
FIG. 2. Proteins with high iTRAQ protein abundance ratios are enriched in hypersecreting B. pseudomallei strains and encoded
within the bsa T3SS locus. A, Boxplot generated by R software (www.r-project.org) showing the distribution and median values of the ratios
of the protein abundances in the 10276 WT (WT), 10276 bipD::pDM4 (bipD), or 10276 bsaP (bsaP) samples compared with the 10276
bsaZ::pDM4 (bsaZ) sample. The “cut-off” values (calculated using R software) are shown by the dotted lines. Points shown above the “cut-off”
value are candidate T3SS effectors. B, A Venn diagram (constructed with Venny: www.bioinfogp.cnb.csic.es/tools/venny) depicting the number
of strain-specific and shared candidate T3SS effector proteins identified in each of the strains 10276 WT (WT), 10276 bipD::pDM4 (bipD), and
10276 bsaP (bsaP). C, Distribution of the candidate T3SS effector proteins plotted according to B. pseudomallei gene number across both
Chromosomes and their ratios. Gene numbers refer to the B. pseudomallei K96243 reference strain. The bsa T3SS locus is indicated by the
red box.
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As expected we observed Bsa-dependent secretion of
BopE in the 10276 WT strain that increased in 10726
bipD::pDM4 and 10276bsaP strains, in full agreement with
Western blot data (Fig. 1). BopC and BopA, the latter of which
has only been proven to be secreted in a T3SS-dependent
manner in EPEC, followed a similar pattern of secretion to
BopE. Although both of the two putative translocator pro-
teins, BipB and BipC, were secreted at higher levels in
10276 WT than 10276 bsaZ::pDM4, only BipB was secreted
at levels above the cut-off ratio of 1.56. Similar to the effect
of Shigella ipaD mutation, the mutation of bipD in B. pseu-
domallei 10276 caused an increase in secretion of both
BipB and BipC into the supernatant compared with 10276
WT. Where 10276 bipD::pDM4 had increased ratios of the
translocators, 10276bsaP showed a decrease in ratios
below that of 10276 WT in agreement with Western blot
data (Fig. 1). This is further evidence that BsaP plays a
similar role in B. pseudomallei to its homolog InvE in Sal-
monella as a “gatekeeper” protein. The only proven effector
missing from this screen was CHBP, however this is not
surprising as we have recently reported that the gene en-
coding CHBP, bpss1385, is absent from the genome of the
B. pseudomallei 10276 strain used here (27).
Besides the needle tip protein BipD, both putative translo-
cators BipB and BipC, BopA, BopC, and BopE, there are also
two hypothetical proteins encoded within the bsa T3SS locus
identified by the screen that have high iTRAQ ratios. The first,
BapA (BPSS1528), is a predicted 880 amino acid protein with
no conserved domains and homologs only in the closely
related species B. mallei and B. thailandensis. Unlike the
TABLE I
Candidate Bsa T3SS effector proteins identified by iTRAQ. The table lists proteins in either the 10276 WT, 10276 bipD::pDM4 or 10276 bsaP
culture supernatant samples that displayed protein abundance ratios (compared to the 10276 bsaZ::pDM4 mutant) higher than the calculated
cut-off values for each comparison. The cut-off values were set at 1.56 for the 10276 WT/10276 bsaZ::pDM4 dataset, 1.79 for the 10276
bipD::pDM4/10276 bsaZ::pDM4 data set, and 1.46 for the 10276 bsaP/10276 bsaZ::pDM4 data set, as described in “Experimental
Procedures.” Additional criteria for protein identification included the presence of at least two unique peptides with a MASCOT peptide score
of 21 corresponding to a 95% confidence level. The proteins are listed in order of gene number with genes from Chromosome one listed first.
Those proteins fulfilling the criteria for selection as candidate T3SS effector proteins are highlighted in the gray shaded boxes. Protein score
refers to the adjusted sum of scores of the individual peptide scores as calculated by MASCOT. Number of unique peptides refers to the number
of significant peptides specific to a protein used in quantification
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known effector proteins in the iTRAQ screen, although secre-
tion of BapA appears to be Bsa-dependent in 10276 WT and
the ratio increases in the 10276 bsaP data set, it does not
appear to be secreted abundantly by the 10276 bipD::pDM4
mutant. Interestingly, under the conditions used we did not
detect BapB or BapC, which are encoded downstream of
BapA in the same operon and predicted to be substrates of
the T3SS (21).
The other candidate effector protein encoded in the bsa
T3SS locus is BprD (BPSS1521), which is annotated as a
hypothetical regulator (48). Predicted to be much smaller than
BapA at 147aa, BprD is another protein with no known con-
served domains and homologs that exist only within closely
related Burkholderia species. The iTRAQ ratios suggest that it
is not secreted at detectable levels by 10276 WT B. pseu-
domallei, but secreted by both 10276 bipD::pDM4 and
10276bsaP, with the ratio of 13.4 in the 10276 bsaP/10276
bsaZ::pDM4 data set being the highest of any protein de-
scribed in this iTRAQ study.
Outside of the Bsa T3SS locus the remaining 18 proteins
with high ratios are distributed across both B. pseudomallei
chromosomes. One of the proteins encoded by a gene closely
flanking the bsa locus is the virulence factor TssM
(BPSS1512), which is known to be coregulated with the Bsa
T3SS as well as secreted in a Type II-dependent manner (72).
Validation of iTRAQ Data by Analysis of the Secretion of
Epitope-Tagged Candidate Effector Proteins—To confirm a
number of targets are secreted in a Bsa-dependent manner, a
number of candidates were selected and cloned into an induc-
ible expression vector as in-frame C-terminal c-Myc tagged
fusion proteins. The targets chosen were BprD, BapA,
BPSS0860, BPSS1512, BopE, and BopA, as well as
BPSS1916, a protein with a very high iTRAQ ratio in all strains
that did not meet the initial selection criteria because of being
quantified with only a single unique peptide. Targets were cho-
sen to represent proteins with both high and low protein scores,
high and low numbers of peptides, and to be encoded inside
and outside of the bsa T3SS locus. The plasmids were trans-
formed into strains 10276 WT, 10276 bsaZ::pDM4, 10276
bipD::pDM4 and 10276bsaP, and bacterial supernatants were
collected and assessed by Western blot for the presence of the
tagged proteins using a c-Myc tag-specific polyclonal antibody.
Initial studies in which BopEwas cloned as a c-Myc fusion in the
widely used shuttle vector pBHR1 under a constitutive chlor-
amphenicol resistance gene promoter indicated that BopE-c-
Myc was secreted in a BsaZ-independent manner, possibly
owing to the high level of expression (data not shown). We
therefore elected to clone effector-c-Myc fusions under an
IPTG-inducible promoter in pME6032 and select inducer levels
at which strict BsaZ-dependent BopE-c-Myc secretion was
observed (Fig. 3). BopA-c-Myc was absent in the supernatant of
the 10276 bsaZ::pDM4 strain, but secreted by the parent strain
and secreted at elevated levels by 10276bsaP (Fig. 3), con-
firming for the first time in B. pseudomallei that it is a substrate
of the Bsa T3SS, not just the locus of enterocyte effacement-
encoded T3SS in EPEC (31). Furthermore, both of the putative
effector proteins located within the bsa locus, BprD-c-Myc and
BapA-c-Myc, were secreted in a BsaZ-dependent manner (Fig.
3), confirming that these are novel effectors of the Bsa
apparatus.
Interestingly, we were unable to validate Bsa-dependent se-
cretion of proteins encoded outside of the Bsa T3SS locus.
BPSS0860 and BPSS1512 appeared in the supernatants of all
strains, including 10276 bsaZ::pDM4, indicating that although
they are secreted, the Bsa system is not required for their
secretion (Fig. 3). Secretion of the protein BPSS1916 could not
be detected in any of the strains tested (Fig. 3). These examples
highlight the need for independent validation of such data sets.
DISCUSSION
B. pseudomallei is an important cause of invasive clinical
disease in South-East Asia and Northern Australia and its
FIG. 3.Western blot analysis of the expression and secretion of
putative B. pseudomallei Bsa T3SS effector proteins expressed
as c-Myc tagged fusion proteins. The coding region of bopE, bopA,
BPSS0860, BPSS1512, BPSS1916, bprD, and bapA were expressed
with a c-terminal c-Myc tag in the IPTG-inducible expression vector
pME6032 in B. pseudomallei strains 10276 WT, 10276 bsaZ::pDM4,
10276 bipD::pDM4 or 10276 bsaP. Supernatant and whole cell
fractions were collected after 6 h of incubation at 37 °C in the pres-
ence of 0.5 mM IPTG. Equal quantities of protein were separated by
reducing SDS-PAGE, blotted onto nitrocellulose membranes and
probed using polyclonal rabbit -c-Myc antibody.
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potential as a bioterrorism agent is cause for concern. One of
the known virulence factors that is important for invasion,
intracellular net replication and virulence in mice is the Bsa
T3SS (21–24), but the repertoire of effector proteins secreted
by the system has not yet been fully characterized. To estab-
lish a better understanding of the Bsa T3SS, we made muta-
tions in key structural components shown to dysregulate
other T3SSs. We show these mutations lead to hypersecre-
tion of known effector proteins. Using these mutants we have
performed a quantitative proteomic analysis of the total se-
cretome of the Bsa T3SS system. This iTRAQ analysis iden-
tified all known effector proteins and translocators present in
B. pseudomallei 10276, as well as identifying a number of
novel putative effector proteins, two of which were independ-
ently validated. Also, examining the changes in the abun-
dance of effectors and translocators secreted by the different
mutants provides insight into the role the proteins likely play in
the temporal regulation of the Bsa T3SS compared with other
T3SSs of other Gram-negative bacteria.
The inability of previous proteomics studies to identify
known Bsa T3SS effectors highlights the need for the use of
more sensitive techniques such as iTRAQ in combination with
genetic dysregulation. The B. pseudomallei secretome is very
complex (supplemental Table S4, supplemental Fig. S3). This
is not surprising when taking into account the large 7.2 Mb
genome (68), which encodes 	5900 proteins, of which over
55% are expressed in LB (73). This study produced one of the
most comprehensive secretomes of B. pseudomallei to date,
identifying a core secretome of 426 proteins secreted under
standard laboratory conditions.
Although known effectors were absent from the secreted
proteome of the bsaZ mutant by Western blotting (Fig. 1) and
largely undetectable by iTRAQ (Table I) implying a lack of cell
lysis, we detected a number of ribosomal proteins that are
enriched in the supernatant when compared with the super-
natant harvested from the 10276 bsaZ::pDM4 strain. This
observation has been made in several other proteomic
screens of T3SS effector repertoires (50, 74–76) and may be
because of a combination of the high abundance of ribosomal
proteins in the bacterial cell coupled with the sensitivity of
iTRAQ.
Concurrent to this study, a proteome analysis investigating
Type II secreted proteins of B. pseudomallei strain MSHR688
was published (72). From our screen, 27 of the 38 proteins
identified as being substrates of Type II secretion in LB by
Burtnick et al. (72) were also identified in our B. pseudomallei
10276 culture supernatants. Whether all 38 Type II secreted
proteins identified in B. pseudomallei MSHR688 are encoded
by B. pseudomallei 10276 is unknown because the genome
sequence for B. pseudomallei 10726 is not yet available.
Interestingly, three of the Type II secreted proteins were en-
riched in the supernatants of the hypersecreting mutants
(BPSL0707, BPSS1512, BPSS1555) and two of the proteins
are encoded by regions flanking the bsa T3SS locus,
BPSS1512 and BPSS1555. The deubiquitinase BPSS1512
(TssM) has been shown to be secreted inside host cells where
it suppresses the host innate immune response (77, 78). Al-
though TssM is secreted independently of the Bsa T3SS, its
expression appears to be coregulated with the Bsa T3SS and
T6SS-5 (78, 79). This coregulation may explain the increased
levels of TssM in the supernatants of the hypersecreting mu-
tants in this study and again highlights the importance of
validating candidate effector proteins.
The profile of secreted proteins encoded within the bsa
T3SS locus provides a comprehensive picture of the secreted
levels of the three known effector proteins. The profiles of
both BopE and BopC in the iTRAQ screen correspond with
previous studies in which they were shown to be secreted in
a Bsa-dependent manner (25, 26). Although BopA has been
shown to be Type 3 secreted in a surrogate host (31), we have
confirmed its secretion to be dependent on the Bsa T3SS in B.
pseudomallei and not one of the other T3SSs.
Two of the putative Bsa T3SS substrates encoded by the
bsa T3SS locus (BapA and BprD) were validated as Bsa-de-
pendent by Western blotting for a C-terminal c-Myc tag.
Although the function of BapA is currently unknown, a bapA
insertion mutation was not attenuated in a Syrian hamster
model of acute melioidosis (23). BprD was previously anno-
tated as a transcriptional regulator (48). In a previous study,
when bprD was deleted along with bprB and bprC, there was
no change in levels of transcription of other Bsa T3SS genes
leaving the role of BprD as a regulator in doubt (48). More
recently, a bprD mutant of B. pseudomallei K96243 was
shown to have increased expression of bprC (80), a down-
stream gene in the same operon shown to be involved in
regulation of the virulence-associated T6SS (81). The bprD
mutant also showed decreased time to death in intraperito-
neally inoculated BALB/c mice demonstrating its importance
in vivo and indicating its possible role as a negative regulator
of virulence (80). It is not without precedent that a regulator of
the T3SS is also a substrate for secretion (e.g. LcrQ of Yers-
inia) (82).
Another candidate protein identified in this study, BPSS0860,
appears to be a fliD homolog. There is a second copy of fliD
(BPSL3320) located within the flagellar locus on Chromosome
1, which had protein abundance ratios that were similar be-
tween all strains. Interestingly, the expression of BPSL3320
was up-regulated, whereas the expression of BPSS0860 was
down-regulated in the organs of hamsters infected by B.
pseudomallei when compared with bacteria grown in vitro
(83). Using our c-Myc expression system we were unable to
establish Bsa-dependent secretion of BPSS0860; however, it
is possible it may be coregulated with the Bsa T3SS in a
similar manner to BPSS1512. One recent study has shown an
effector protein may be secreted by more than one secretion
system, thereby masking its secretion by the T3SS (84). This
could also be the case for BPSS0860.
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At the time of writing, little is known about the post-trans-
lational control of the Bsa T3SS. Generally it is accepted that
T3SSs are under tight temporal regulation to ensure sub-
strates are secreted in the correct order (17). This starts with
assembly of the membrane-associated structural compo-
nents, assembly of the needle with needle tip, secretion of
translocators to form a pore in the host cell membrane, fol-
lowed by secretion of effector proteins. Changes in the pat-
terns of secreted translocators and effector proteins in differ-
ent mutant strains can inform us of the possible role these
proteins play in the hierarchy of secretion.
Inactivation of the needle tip protein of B. pseudomallei, BipD,
shows a large increase of levels of both translocators and
effectors in the culture supernatant, in agreement with data
published for the homologous Shigella protein IpaD (46, 52).
IpaD is the needle cap protein, acting to block secretion of
effector proteins until host cell contact has taken place (85).
Because of its high similarity in both sequence and structure
(53) it is perhaps unsurprising that BipD would have a similar
effect on the levels of substrates secreted by the Bsa T3SS.
Interestingly there was a high ratio of BipB, but not BipC in the
WT B. pseudomallei 10276 strain culture supernatant compared
with 10276 bsaZ::pDM4 (Table I). In Shigella, IpaB is present in
the needle tip in complex with IpaD, whereas IpaC is secreted
later, only upon host cell contact or activation (86). With this in
mind it is possible that growth in LB lacks the stimuli required for
BipC secretion in WT B. pseudomallei 10276.
Here we present evidence that BsaP functions as a “gate-
keeper” protein for effectors in a manner similar to the homol-
ogous T3SS proteins InvE/SepL/MxiC/YopN-TyeA (54–60).
Members of this family of proteins function differently from
each other, but are all thought to be important in allowing
effectors to be secreted by the mature T3SS. Here we show
that deletion of bsaP creates a phenotype in which effector
proteins are hypersecreted and levels of translocators de-
crease. To fully understand BsaP in the context of the other
members of the “gatekeeper” family of proteins, more work
would be required to determine the molecular interactions of
BsaP with other components of the Bsa T3SS.
This study is another example of the power of a combina-
tion of classic targeted mutagenesis and a gel-free quantita-
tive proteomics approach, such as iTRAQ, to study a complex
secretion system, providing insights into the involvement of
certain proteins on the regulation of the T3SS itself. Two new
substrates of the Bsa T3SS were revealed by the study,
confirming the effector repertoire is more complex than re-
ported so far.
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